WestEnd Advisors’s Quest Diagnostics DGX Stock Holding History

WestEnd Advisors’s Portfolio DGX Stock Details DGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$699	Hold	3	–	–	﹤0.01%	331
2026 Q2	$636	Hold	3	–	–	﹤0.01%	326
2026 Q1	$588	Hold	3	–	–	﹤0.01%	300
2025 Q4	$521	Hold	3	–	–	﹤0.01%	309
2025 Q3	$572	Sell	3 -1	-25%	-$177	﹤0.01%	295
2025 Q2	$719	Hold	4	–	–	﹤0.01%	240
2025 Q1	$677	Buy	4 +3	+300%	+$493	﹤0.01%	244
2024 Q4	$151	Hold	1	–	–	﹤0.01%	287
2024 Q3	$155	Hold	1	–	–	﹤0.01%	319
2024 Q2	$137	Sell	1 -1	-50%	-$137	﹤0.01%	299
2024 Q1	$266	Hold	2	–	–	﹤0.01%	224
2023 Q4	$276	Hold	2	–	–	﹤0.01%	207
2023 Q3	$244	Buy	+2	New	+$266	﹤0.01%	212
2023 Q1	–	Sell	-1	Closed	-$143	–	258
2022 Q4	$156	Hold	1	–	–	﹤0.01%	248
2022 Q3	$0	Hold	1	–	–	﹤0.01%	182
2022 Q2	$132	Buy	+1	New	+$136	﹤0.01%	252
2022 Q1	–	Sell	-1	Closed	-$139	–	270
2021 Q4	$173	Buy	+1	New	+$152	﹤0.01%	286
2021 Q3	–	Hold	0	–	–	–	288
2021 Q2	–	Hold	0	–	–	–	301

Other funds holding DGX

DekaBank Deutsche Girozentrale Frankfurt, Germany $87.8B AUM 20.94% 1-Year Est. Return

Artemis Investment Management Edinburgh, United Kingdom $11.5B AUM 61.77% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $174B AUM 33.96% 1-Year Est. Return

Eastern Bank Boston, Massachusetts $6.58B AUM 23.57% 1-Year Est. Return

Conning Inc Hartford, Connecticut $3.25B AUM 18.91% 1-Year Est. Return

Cookson Peirce & Co Pittsburgh, Pennsylvania $2.77B AUM 64.09% 1-Year Est. Return

Braun Stacey Associates New York $3.48B AUM 48.73% 1-Year Est. Return

Achmea Investment Management Zeist, Netherlands $12.6B AUM 25.68% 1-Year Est. Return

Willis Investment Counsel Gainesville, Georgia $1.97B AUM 25.29% 1-Year Est. Return

Copeland Capital Management Conshohocken, Pennsylvania $4.34B AUM 17.52% 1-Year Est. Return

WestEnd Advisors's DGX Position: Q3 2026 in Review

WestEnd Advisors held its Quest Diagnostics (DGX) position steady in Q3 2026 at 3 shares worth $699. The position accounts for ﹤0.01% of the portfolio, ranked #331.

WestEnd Advisors first reported a position in DGX in Q4 2021 and has held it in 17 quarters since. The position peaked at $719 in Q2 2025. 414 funds tracked by Wall St. Rank hold DGX as of Q3 2026.

WestEnd Advisors held 3 shares of Quest Diagnostics worth $699 as of Q3 2026.
WestEnd Advisors left its Quest Diagnostics share count unchanged in Q3 2026.
Quest Diagnostics made up ﹤0.01% of WestEnd Advisors's portfolio in Q3 2026, its #331 holding.
WestEnd Advisors first reported a position in Quest Diagnostics in Q4 2021 and has held it in 17 quarters since.
WestEnd Advisors's Quest Diagnostics position peaked at $719 in Q2 2025.
414 funds tracked by Wall St. Rank held Quest Diagnostics as of Q3 2026.

Based on WestEnd Advisors's 13F filing for Q3 2026, filed 27 Oct 2026.